GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteostasis Therapeutics Inc (NAS:PTI) » Definitions » EPS without NRI

Proteostasis Therapeutics (Proteostasis Therapeutics) EPS without NRI : $-15.00 (TTM As of Sep. 2020)


View and export this data going back to 2016. Start your Free Trial

What is Proteostasis Therapeutics EPS without NRI?

Proteostasis Therapeutics's earnings per share without non-recurring items for the three months ended in Sep. 2020 was $-3.20. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2020 was $-15.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Proteostasis Therapeutics's EPS without NRI or its related term are showing as below:

PTI's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 4.95
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Proteostasis Therapeutics's EPS (Diluted) for the three months ended in Sep. 2020 was $-3.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $-15.00.

Proteostasis Therapeutics's EPS (Basic) for the three months ended in Sep. 2020 was $-3.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2020 was $-15.00.


Proteostasis Therapeutics EPS without NRI Historical Data

The historical data trend for Proteostasis Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteostasis Therapeutics EPS without NRI Chart

Proteostasis Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EPS without NRI
Get a 7-Day Free Trial -27.90 -41.20 -46.80 -32.20 -23.20

Proteostasis Therapeutics Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.00 -4.60 -3.80 -3.40 -3.20

Competitive Comparison of Proteostasis Therapeutics's EPS without NRI

For the Biotechnology subindustry, Proteostasis Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proteostasis Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteostasis Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Proteostasis Therapeutics's PE Ratio without NRI falls into.



Proteostasis Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proteostasis Therapeutics  (NAS:PTI) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Proteostasis Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Proteostasis Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Proteostasis Therapeutics (Proteostasis Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
80 Guest Street, Suite 500, 5th Floor, Boston, MA, USA, 02135
Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. All of the company's revenue is collaboration or license revenue earned from activities in the United States.
Executives
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Badrul A. Chowdhury director PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Jeffrey W. Kelly director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Emmanuel Dulac director PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
David Arkowitz director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael Alfieri officer: Interim Head of Finance C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Greffrey S. Gilmartin officer: Chief Medical Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Meenu Chhabra director, officer: President and CEO C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Sheila Wilson officer: Chief Operating Officer C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Benito Munoz officer: Chief Scientific Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Eric D Larson officer: See Remarks C/O NORTHERN POWER SYSTEMS CORP., 29 PITMAN ROAD, BARRE VT 05641
Marija Zecevic officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202

Proteostasis Therapeutics (Proteostasis Therapeutics) Headlines

From GuruFocus